Luspatercept: From Bench to Bedside and Beyond in the Management of Ineffective Erythropoiesis - PubMed
4 hours ago
- #Ineffective Erythropoiesis
- #Hematologic Disorders
- #Luspatercept
- Luspatercept is a novel erythroid maturation agent that targets the transforming growth factor-β superfamily to enhance late-stage erythroid differentiation.
- It shows clinical efficacy in treating ineffective erythropoiesis in conditions like lower-risk myelodysplastic syndromes, transfusion-dependent β-thalassemia, and myelofibrosis.
- Benefits include improvements in erythroid response and achievement of transfusion independence, with a review of its adverse event profile.
- Future directions involve ongoing trials and potential expansion of its indications in hematologic disorders.